New deputy in town
This article was originally published in The Tan Sheet
Executive Summary
Curtis Rosebraugh, MD, took over as CDER Division of OTC Drug Products deputy director effective Jan. 27. Rosebraugh has previously worked as a medical officer in the Division of Pulmonary & Allergy Drug Products, which could affect the extent to which the OTC drug division attempts to initiate Rx-to-OTC switches of the remaining second-generation antihistamines. Rosebraugh replaces Linda Katz, MD, who left to head the Office of Cosmetics & Colors Sept. 3. Rosebraugh will report to Division of OTC Drug Products Director Charles Ganley, MD...
You may also be interested in...
ODE II director
FDA names Curtis Rosebraugh director of the Office of Drug Evaluation II after nine months as acting director of the office in the Center for Drug Evaluation and Research. He will oversee the divisions of Anesthesia, Analgesia and Rheumatology Products, Metabolism and Endocrinology Products and Pulmonary and Allergy Products. Rosebraugh from 2003-2005 served as deputy director of the Office of Nonprescription Products, with responsibilities including acting director of ONP's Division of Nonprescription Clinical Evaluation (1"The Tan Sheet" Feb. 10, 2003, In Brief). In 2005 he was named deputy director of the ODE II and became acting director in September 2007...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.